Varizig Injection, Solution
NDC Package 49591-126-51

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Varizig (human varicella-zoster immune globulin) injection is a medication used to help provide protection (antibodies) against a certain virus infection (varicella zoster) commonly known as chickenpox. This formulation utilizes a injection, solution delivery system. Marketed by Kamada Ltd., this product is identified by NDC 49591-126 and is authorized under FDA application BLA125430.

Identification & Billing

NDC Package Code
49591-126-51
Package Description
1 VIAL, GLASS in 1 CARTON / 1.2 mL in 1 VIAL, GLASS (49591-126-11)
Product Code
49591-126
11-Digit Billing Format
49591012651
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Varizig
Non-Proprietary Name
Human Varicella-zoster Immune Globulin
Substance Name
Human Varicella-zoster Immune Globulin
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Intramuscular - Administration within a muscle.
Active Ingredient(s)
HUMAN VARICELLA-ZOSTER IMMUNE GLOBULIN 125 [iU]/1.2mL
Usage Information
This medication is used to help provide protection (antibodies) against a certain virus infection (varicella zoster) commonly known as chickenpox. It is used by certain people who have not been vaccinated or had the infection before and have had recent contact with someone infected with chickenpox. This medication is made from healthy human blood that has high levels of a certain substance (varicella zoster antibodies) which helps fight the infection. Routine vaccination is usually the best way to protect against infection.

Regulatory & Marketing

Labeler Name
Kamada Ltd.
Product Type
Plasma Derivative
FDA Application #
BLA125430
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
03-01-2024
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

90396
Source: OPPS
Varicella-zoster ig im
HCPCS Dosage 125 IU
Units / Pkg 1

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 49591-126-51 identifies a specific commercial package of 1 vial, glass in 1 carton / 1.2 ml in 1 vial, glass (49591-126-11) of Varizig, a plasma derivative labeled by Kamada Ltd.. This injection, solution is formulated for intramuscular use and contains human varicella-zoster immune globulin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Kamada Ltd. on March 01, 2024. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to help provide protection (antibodies) against a certain virus infection (varicella zoster) commonly known as chickenpox. It is used by certain people who have not been vaccinated or had the infection before and have had recent contact with someone infected with chickenpox. This medication is made from healthy human blood that has high levels of a certain substance (varicella zoster antibodies) which helps fight the infection. Routine vaccination is usually the best way to protect against infection.

How is this Kamada Ltd. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 49591012651. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
49591-126-51
11-Digit CMS (5-4-2)
49591-0126-51

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.